Starling Oncology, Inc. · Brief

Next report

12 days

Nov 12 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

2 of 6≥ implied

Mar 24 '25—▲+24.47%—

May 14 '25—▲+28.27%—

Aug 13 '25±16.2%▼−10.49%×0.65

Q3 FY25±13.7%▲+28.90%×2.11

Jan 12 '26±9.3%▼−7.89%×0.85

Q1 FY26±75.8%▲+8.40%×0.11

May 7 '26±18.3%▼−1.72%×0.09

Q2 FY26±13.5%▲+28.46%×2.11

quarterimplied−80%0+80%realized×

Q2 FY26±13.5%▲+28.46%×2.11

May '26±18.3%▼−1.72%×0.09

Q1 FY26±75.8%▲+8.40%×0.11

Jan '26±9.3%▼−7.89%×0.85

Q3 FY25±13.7%▲+28.90%×2.11

Aug '25±16.2%▼−10.49%×0.65

2 older reports

May '25—▲+28.27%—

Mar '25—▲+24.47%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 12 report · est.

Bull2 of 3

8disclosed supplier and customer ties in SEC filingsSEC filings

120managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2

21managers holding four fifths of reported value13F · Jun 30 '26

4 of 22of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Oct 7 '26once per report · top 2 per case

TOI report session

No linked exposure.

No changes.

privateThesis 0 · Decisions 0 · Observations 0

No thesis.